Trending News

#Covid-19 #Immunology / Virology & Vaccines #mRNA

UK government invests £5m into Covid-19 variant vaccines

Budget Chancellor Rishi Sunak announced a £5 million investment in CPI to develop an mRNA ‘vaccine library’, as part of the government’s vaccines support package. The vaccine library will form the basis of a rapid response facility, enabling mRNA vaccines to be developed to help protect against new variants of… Read More

#News #Trending News

#Immunology / Virology & Vaccines #Life sciences #mRNA #Pharmaceutical

What the UK Budget means for the pharma sector: industry reaction

By Lu Rahman In his 2021 Budget, UK Chancellor of the Exchequer, Rishi Sunak, announced a range of measures designed to benefit UK science, business and technology. These included tax breaks for firms to designed to ‘unlock’ £20bn worth of business investment; incentives for companies to take on apprentices; allowing… Read More

#Editor's Choice #News #Trending News

#Clinical trials #Covid-19 #Immunology / Virology & Vaccines

COVID-19 vaccine pill a possibility?

Professor Sarah Gilbert, head of the team behind the Oxford AstraZeneca COVID-19 vaccine, has told UK MPs that there is a possibility the vaccine could be taken orally and perhaps also via a nasal spray. Reported in The Guardian newspaper today, she was asked by MP Graham Stringer how the… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Biotechnology #Drug development #Drug discovery

Quotient Sciences CEO talks acquisitions, efficiency and finding cures fast

Mark Egerton, Chief Executive Officer, Quotient Sciences, spoke to Lu Rahman about the company’s acquisition of Arcinova and what it means for the drug discovery sector. Quotient Sciences, the drug development and manufacturing accelerator, recently acquired Arcinova, the UK-based multiservice contract development and manufacturing organisation (CDMO). Boasting over 40 years of… Read More

#Editor's Choice #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

Pfizer and AstraZeneca COVID-19 vaccine working, suggests Scottish study

The study is the first to describe across an entire country the effect of the Pfizer and Oxford-AstraZeneca jabs in the community on preventing severe illness resulting in hospitalisation. Previous results about vaccine efficacy have come from clinical trials. Hospitalisation drop By the fourth week after receiving the initial dose,… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Clinical trials #Covid-19 #Immunology / Virology & Vaccines

Sanofi and GSK start new Phase II study of their COVID-19 vaccine candidate

Sanofi and GlaxoSmithKline (GSK) have begun a new Phase II study with 720 volunteers aged 18 and over to select the most appropriate antigen dosage for Phase III evaluation of their adjuvanted recombinant protein COVID-19 vaccine candidate. “Over the past few weeks, our teams have worked to refine the antigen… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Clinical trials #Covid-19 #Human trials #Immunology / Virology & Vaccines

World’s first coronavirus Human Challenge study receives ethics approval

The UK will be the first country in the world to run a COVID-19 human challenge study, following approval from the UK’s clinical trials ethics body. Backed by a £33.6 million UK government investment, the first-of-its-kind study for this virus will involve establishing the smallest amount of virus needed to… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

Oxford vaccine data on protection against COVID-19 infection from South African variant

In an analysis, submitted as a pre-print prior to peer-review publication, a two-dose regimen of the ChAdOx1 nCoV-19 vaccine provides minimal protection against mild-moderate COVID-19 infection from the B.1.351 coronavirus variant first identified in South Africa. Efficacy against severe COVID-19 infection from this variant was not assessed. The analyses being… Read More

#Covid-19 #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

Oxford AstraZeneca vaccine effective against ‘Kent’ variant

A preprint of ongoing work to assess effectiveness of Oxford’s ChAdOx1 coronavirus vaccine shows that the existing vaccine has similar efficacy against the B.1.1.7 ‘Kent’ coronavirus strain currently circulating in the UK to previously circulating variants. The Oxford University researchers who developed the ChAdOx1-nCoV 19 vaccine have found that it… Read More

#Editor's Choice #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines #Research

Oxford University leads first trial into dosing with alternating vaccines

The University of Oxford has reported  it is to lead the first trial looking into alternating different COVID-19 vaccines, to explore the potential for flexibility in delivery and look for clues as to how to increase the breadth of protection against new virus strains. The study, run by the National… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

GSK and CureVac collaboration to develop COVID-19 vaccine for multi-variants

GlaxoSmithKline and CureVac have signed a €150m (£132m) deal to jointly develop next generation mRNA vaccines for COVID-19. They aim to work together to develop a single vaccine that can address the multiple emerging variants. GSK will also support the manufacture of up to 100 million doses of CureVac’s first… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

Janssen COVID-19 vaccine: 66% efficacy in one shot

An investigational COVID-19 vaccine developed by Janssen Pharmaceuticals appears to be safe and effective at preventing moderate and severe COVID-19 in adults, according to an interim analysis of Phase III clinical data. The vaccine, called Ad.26.COV2.S or JNJ-78436725, requires only a single injection and can be stored in a refrigerator… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

Novavax COVID-19 vaccine demonstrates 89.3% efficacy

Novavax, the biotechnology company developing next-generation vaccines for serious infectious diseases, has announced that NVX-CoV2373, its protein-based COVID-19 vaccine candidate, met the primary endpoint, with a vaccine efficacy of 89.3%, in its Phase III clinical trial conducted in the UK. The study assessed efficacy during a period with high transmission… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Immunotherapy #Oncology

Genetic changes in tumours could help predict if patients will respond to immunotherapy

Researchers at the Francis Crick Institute, the UCL Cancer Institute, and the Cancer Research UK Lung Cancer Centre of Excellence have identified genetic changes in tumours which could be used to predict if immunotherapy drugs would be effective in individual patients. Immunotherapies have led to huge progress treating certain types… Read More

#Cancer Research #Editor's Choice #News #Trending News